Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Small Bowel

Free Access

Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Consensus Issues

Cuomo R. · Savarese M.F. · Gargano R.

Author affiliations

Gastroenterological Unit, Department of Clinical and Experimental Medicine, University of Naples ‘Federico II’, Naples, Italy

Corresponding Author

Prof. Rosario Cuomo, MD

Department of Clinical and Experimental Medicine

Gastroenterological Unit, University ‘Federico II’

Via Sergio Pansini 5, IT–80131 Naples (Italy)

Tel./Fax +39 081 746 3892, E-Mail rcuomo@unina.it

Related Articles for ""

Dig Dis 2007;25:241–244

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Several reports have described post-infectious irritable bowel syndrome (Pi-IBS), while many animal and human studies have shown the presence of increased infiltration of inflammatory cells and hyperplasia of enterochromaffin cells in the intestinal mucosa after acute gastroenteritis. The potential value of probiotic bacteria in restoring normal gut function has been demonstrated by animal models of Pi-IBS. In humans, Pi-IBS can be prevented utilizing probiotics to reduce the duration of acute gastroenteritis, despite the variable efficacy shown in randomized control trials evaluating unspecified IBS. Here, advances in the pathophysiology supporting the post-infectious hypothesis are considered. In addition, the current role of probiotics in the management of Pi-IBS is discussed.

© 2007 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Small Bowel

Published online: September 10, 2007
Issue release date: September 2007

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: http://www.karger.com/DDI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.